Drugs / CARv3-TEAM-E T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05660369 | Mar 2023 → Sep 2026 overdue | glioblastoma | Massachusetts General Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CARv3-TEAM-E T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05660369 ↗ |
| Action | Deplete | “CARv3-TEAM-E T Cells are made from a person's own collected immune cells (T-Cells) that are genetically changed and then delivered back into the body to try to kill their...” NCT05660369 ↗ |
| Modality | Cell therapy | “CAR T cells engineered” PMID 38477966 ↗ Mar 2024 |
| Route | Other | “single intraventricular infusion” PMID 38477966 ↗ Mar 2024 |
| Target | EGFR | “engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen” PMID 38477966 ↗ Mar 2024 |